In return for the rights granted to it, Medical Futures will make an upfront payment to Norgine as well as further milestones and royalty payments on sales. The precise details of the deal have not been disclosed.
Moviprep is a novel patent-protected product developed by Norgine for bowel cleansing prior to colonoscopy and other situations where a clean bowel is required. The product is marketed by Norgine in Europe and in the US by its partner Salix Pharmaceuticals.
Par Nijhawan, chief medical officer of Medical Futures, said: “This agreement with Norgine underlines Medical Futures’s commitment to the prevention and treatment of gastrointestinal diseases.”